Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses: 2021-2024

Historic Other Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $16.1 million.

  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses rose 27.72% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 27.72%. This contributed to the annual value of $16.1 million for FY2024, which is 96.23% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Other Accumulated Expenses is $16.1 million, which was up 96.23% from $8.2 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Other Accumulated Expenses ranged from a high of $25.0 million in FY2021 and a low of $8.2 million during FY2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Other Accumulated Expenses value was $8.4 million (recorded in 2022), while the average stood at $10.9 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Other Accumulated Expenses tumbled by 66.46% in 2022 and then spiked by 96.23% in 2024.
  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses (Yearly) stood at $25.0 million in 2021, then slumped by 66.46% to $8.4 million in 2022, then decreased by 2.21% to $8.2 million in 2023, then surged by 96.23% to $16.1 million in 2024.